[go: up one dir, main page]

MXPA04005444A - Ureas de 2-aminobenzotiazoles como moduladores de adenosina. - Google Patents

Ureas de 2-aminobenzotiazoles como moduladores de adenosina.

Info

Publication number
MXPA04005444A
MXPA04005444A MXPA04005444A MXPA04005444A MXPA04005444A MX PA04005444 A MXPA04005444 A MX PA04005444A MX PA04005444 A MXPA04005444 A MX PA04005444A MX PA04005444 A MXPA04005444 A MX PA04005444A MX PA04005444 A MXPA04005444 A MX PA04005444A
Authority
MX
Mexico
Prior art keywords
aminobenzothiazoles
ureas
adenosine
adenosine modulators
disease
Prior art date
Application number
MXPA04005444A
Other languages
English (en)
Inventor
David Norcross Roger
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MXPA04005444A publication Critical patent/MXPA04005444A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C07D451/06—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/06—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing isoquinuclidine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/08—Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Vascular Medicine (AREA)
  • Anesthesiology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

la presente invencion se refiere al uso de compuestos de formula general (I)(ver formula I)y las sales de adicion de acido farmaceuticamente aceptables de los mismos para la fabricacion de medicamentos para el tratamiento de enfermedades relacionadas con el sistema receptor de adenosina A2, como la enfermedad de parkinson, ansiedad, dolor y otros trastornos neurologicos.
MXPA04005444A 2001-12-10 2002-12-05 Ureas de 2-aminobenzotiazoles como moduladores de adenosina. MXPA04005444A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01129228 2001-12-10
PCT/EP2002/013761 WO2003049741A1 (en) 2001-12-10 2002-12-05 Ureas of 2-aminobenzothiazoles as adenosine modulators

Publications (1)

Publication Number Publication Date
MXPA04005444A true MXPA04005444A (es) 2004-10-11

Family

ID=8179478

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA04005444A MXPA04005444A (es) 2001-12-10 2002-12-05 Ureas de 2-aminobenzotiazoles como moduladores de adenosina.

Country Status (20)

Country Link
US (2) US6727247B2 (es)
EP (1) EP1455792B1 (es)
JP (1) JP4245483B2 (es)
KR (1) KR100659793B1 (es)
CN (1) CN1602196A (es)
AR (1) AR037731A1 (es)
AT (1) ATE359792T1 (es)
AU (1) AU2002356626B2 (es)
BR (1) BR0214825A (es)
CA (1) CA2469596A1 (es)
DE (1) DE60219682T2 (es)
ES (1) ES2283652T3 (es)
GT (1) GT200200266A (es)
MX (1) MXPA04005444A (es)
PA (1) PA8559901A1 (es)
PE (1) PE20030759A1 (es)
PL (1) PL371063A1 (es)
RU (1) RU2311905C2 (es)
TW (1) TW200409628A (es)
WO (1) WO2003049741A1 (es)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
YU96502A (sh) * 2000-06-21 2006-01-16 F. Hoffmann-La Roche Ag. Derivati benzotiazola
EP1231212B1 (en) * 2001-02-06 2006-12-20 Pfizer Products Inc. Pharmaceutical compositions for the treatment of disorders of the CNS and other disorders
US6727247B2 (en) * 2001-12-10 2004-04-27 Hoffman-La Roche Inc. Substituted benzothiazole amide derivatives
ES2464157T3 (es) * 2002-06-26 2014-05-30 Ono Pharmaceutical Co., Ltd. Remedios para enfermedades causadas por contracción o dilatación vascular
HRP20160180T1 (hr) 2003-04-24 2016-03-25 Incyte Holdings Corp Derivati aza spiro alkana kao inhibitori metaloproteaza
EP1636223B1 (en) 2003-05-19 2008-03-19 F. Hoffman-la Roche AG Benzothiazole derivatives as adenosine receptor ligands
NZ543372A (en) * 2003-05-30 2008-11-28 Hoffmann La Roche Benzothiazole derivatives and use thereof in the treatment of diseases related to the adenoside A2A receptor
KR20060058132A (ko) 2003-09-19 2006-05-29 에프. 호프만-라 로슈 아게 아데노신 수용체 리간드로서의 싸이아졸로피리딘 유도체
EP1677791A4 (en) 2003-10-31 2007-08-15 Takeda Pharmaceutical NITROGENIC CONDENSED HETEROCYCLIC COMPOUNDS
ATE499373T1 (de) 2004-01-08 2011-03-15 Hoffmann La Roche Diazaspiropiperidinderivate
KR100834179B1 (ko) * 2004-05-24 2008-05-30 에프. 호프만-라 로슈 아게 4-하이드록시-4-메틸-피페리딘-1-카복실산(4-메톡시-7-모폴린-4-일-벤조티아졸-2-일)-아마이드
NZ550763A (en) * 2004-05-24 2010-07-30 Hoffmann La Roche 4-hydroxy-4-methyl-piperidine-1-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide
EP1773795A1 (en) * 2004-07-22 2007-04-18 F.Hoffmann-La Roche Ag Substituted benzothiazoles
SG140605A1 (en) * 2004-07-22 2008-03-28 Hoffmann La Roche Benzothiazole derivatives
EA012589B1 (ru) 2004-12-30 2009-10-30 Янссен Фармацевтика Н.В. Производные фениламида 4-(бензил)пиперазин-1-карбоновой кислоты и родственные соединения в качестве модуляторов амида жирной кислоты гидролазы для лечения страхов, боли и других состояний
KR100973609B1 (ko) 2005-03-23 2010-08-03 에프. 호프만-라 로슈 아게 ｍＧｌｕＲ2 길항제로서 아세틸렌일-피라졸로-피리미딘유도체
CN101273040B (zh) 2005-09-27 2011-11-09 弗·哈夫曼-拉罗切有限公司 作为mglur2拮抗剂的*二唑基吡唑并嘧啶类化合物
US8841334B2 (en) 2006-05-31 2014-09-23 Abbvie Inc. Compounds as cannabinoid receptor ligands and uses thereof
EP2024349B1 (en) 2006-05-31 2017-08-02 AbbVie Inc. Compounds as cannabinoid receptor ligands and uses thereof
WO2007143600A2 (en) * 2006-06-05 2007-12-13 Incyte Corporation Sheddase inhibitors combined with cd30-binding immunotherapeutics for the treatment of cd30 positive diseases
US20070299089A1 (en) * 2006-06-22 2007-12-27 Cv Therapeutics, Inc. Use of A2A Adenosine Receptor Agonists in the Treatment of Ischemia
JPWO2008023720A1 (ja) * 2006-08-23 2010-01-14 アステラス製薬株式会社 ウレア化合物又はその塩
CL2007003827A1 (es) * 2006-12-28 2008-09-26 Actelion Pharmaceuticals Ltd Compuestos derivados de n-(2-aza-biciclo(3.1.0)hex-3-ilmetil)amida; y su uso para prevenir o tratar la depresion, neurosis, esquizofrenia, ansiedad, adicciones, epilepsia, dolor, enfermedades cardiacas, entre otras.
CA2681586A1 (en) 2007-03-28 2008-10-09 Abbott Laboratories 1, 3-thiazol-2 (3h) -ylidene compounds as cannabinoid receptor ligands
US7872033B2 (en) 2007-04-17 2011-01-18 Abbott Laboratories Compounds as cannabinoid receptor ligands
MX2009012374A (es) 2007-05-18 2009-12-01 Abbott Lab Compuestos novedosos como ligandos del receptor de canabinoides.
CA2688343A1 (en) * 2007-05-25 2008-12-18 Janssen Pharmaceutica N.V. Heteroaryl-substituted urea modulators of fatty acid amide hydrolase
WO2009011872A1 (en) 2007-07-17 2009-01-22 Merck & Co., Inc. Soluble epoxide hydrolase inhibitors, compositions containing such compounds and methods of treatment
US9193713B2 (en) 2007-10-12 2015-11-24 Abbvie Inc. Compounds as cannabinoid receptor ligands
US9226907B2 (en) 2008-02-01 2016-01-05 Abbvie Inc. Extended release hydrocodone acetaminophen and related methods and uses thereof
US8846730B2 (en) 2008-09-08 2014-09-30 Abbvie Inc. Compounds as cannabinoid receptor ligands
RU2011115087A (ru) 2008-09-16 2012-10-27 Эбботт Лэборетриз (Us) Замещенные бензамиды в качестве лигандов каннабиноидного рецептора
US8461159B2 (en) * 2008-11-25 2013-06-11 Jannsen Pharmaceutica BV Heteroaryl-substituted urea modulators of fatty acid amide hydrolase
US8598356B2 (en) * 2008-11-25 2013-12-03 Janssen Pharmaceutica Nv Heteroaryl-substituted urea modulators of fatty acid amide hydrolase
PA8854001A1 (es) 2008-12-16 2010-07-27 Abbott Lab Compuestos novedosos como ligandos de receptores de canabinoides
FR2945531A1 (fr) * 2009-05-12 2010-11-19 Sanofi Aventis Derives de 7-aza-spiro°3,5!nonane-7-carboxylates, leur preparation et leur application en therapeutique
WO2010141817A1 (en) 2009-06-05 2010-12-09 Janssen Pharmaceutica Nv Heteroaryl-substituted spirocyclic diamine urea modulators of fatty acid amide hydrolase
WO2010141809A1 (en) 2009-06-05 2010-12-09 Janssen Pharmaceutica Nv Aryl-substituted heterocyclic urea modulators of fatty acid amide hydrolase
WO2011021645A1 (ja) * 2009-08-19 2011-02-24 大日本住友製薬株式会社 ２環性ウレア誘導体、またはその薬学的に許容される塩
UA108233C2 (uk) 2010-05-03 2015-04-10 Модулятори активності гідролази амідів жирних кислот
RU2696278C2 (ru) * 2012-07-18 2019-08-01 Юниверсити Оф Нотр Дам Дю Лак 5,5-гетероароматические противоинфекционные соединения
WO2014146995A1 (en) * 2013-03-20 2014-09-25 F. Hoffmann-La Roche Ag Urea derivatives and their use as fatty-acid binding protein (fabp) inhibitors
BR112015024113A2 (pt) * 2013-03-20 2017-07-18 Hoffmann La Roche derivados de uréia e seu uso como inibidores da proteína de ligação de ácido graxo (fabp)
CN117777121A (zh) * 2016-10-24 2024-03-29 詹森药业有限公司 化合物及其用途
KR20190108118A (ko) 2017-01-06 2019-09-23 유마니티 테라퓨틱스, 인크. 신경계 장애의 치료를 위한 방법
WO2019084157A1 (en) 2017-10-24 2019-05-02 Yumanity Therapeutics, Inc. COMPOUNDS AND USES THEREOF
WO2019141096A1 (zh) * 2018-01-19 2019-07-25 四川科伦博泰生物医药股份有限公司 取代脲类化合物及其制备方法和用途
JP7517992B2 (ja) 2018-03-23 2024-07-17 ヤンセン ファーマシューティカ エヌ．ベー． 化合物及びその使用
WO2020103930A1 (zh) * 2018-11-22 2020-05-28 上海科技大学 噻唑并环类化合物、其制备方法、中间体和应用
BR112021014583A2 (pt) 2019-01-24 2021-10-05 Yumanity Therapeutics, Inc. Compostos e utilizações dos mesmos
EA202192047A1 (ru) 2019-11-13 2021-12-08 Юманити Терапьютикс, Инк. Соединения и их применение

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US45615A (en) * 1864-12-27 Improvement in cultivators
US3954766A (en) 1975-07-09 1976-05-04 Stanford Research Institute 1,4-Diazabicyclo[3.2.1]octanes
DE3374550D1 (en) 1982-12-21 1987-12-23 Johnsen Jorgensen Plastics Ltd Dispensing container
DE4241013A1 (de) * 1992-12-05 1994-06-09 Boehringer Ingelheim Kg Verwendung von 2-Amino-6-n-propyl-amino-4,5,6,7-tetrahydrobenzothiazol als Arzneimittel mit antidepressiver Wirkung
WO2001057008A1 (en) 2000-02-07 2001-08-09 Abbott Gesellschaft Mit Beschrankter Haftung & Company Kommanditgesellschaft 2-benzothiazolyl urea derivatives and their use as protein kinase inhibitors
YU96502A (sh) * 2000-06-21 2006-01-16 F. Hoffmann-La Roche Ag. Derivati benzotiazola
US6599901B1 (en) * 2001-11-19 2003-07-29 Hoffman-La Roche Inc. Pyridone substituted benzothiazole derivatives
US6727247B2 (en) * 2001-12-10 2004-04-27 Hoffman-La Roche Inc. Substituted benzothiazole amide derivatives

Also Published As

Publication number Publication date
TW200409628A (en) 2004-06-16
DE60219682T2 (de) 2008-01-17
KR100659793B1 (ko) 2006-12-19
AU2002356626A1 (en) 2003-06-23
GT200200266A (es) 2003-07-03
JP4245483B2 (ja) 2009-03-25
RU2004121166A (ru) 2005-05-10
AR037731A1 (es) 2004-12-01
WO2003049741A1 (en) 2003-06-19
US20030149036A1 (en) 2003-08-07
CN1602196A (zh) 2005-03-30
PA8559901A1 (es) 2003-09-05
PE20030759A1 (es) 2003-09-05
PL371063A1 (en) 2005-06-13
EP1455792B1 (en) 2007-04-18
DE60219682D1 (de) 2007-05-31
US6727247B2 (en) 2004-04-27
BR0214825A (pt) 2004-09-14
KR20040065576A (ko) 2004-07-22
US7019001B2 (en) 2006-03-28
RU2311905C2 (ru) 2007-12-10
AU2002356626B2 (en) 2007-11-29
EP1455792A1 (en) 2004-09-15
US20040229893A1 (en) 2004-11-18
ATE359792T1 (de) 2007-05-15
CA2469596A1 (en) 2003-06-19
JP2005516006A (ja) 2005-06-02
ES2283652T3 (es) 2007-11-01

Similar Documents

Publication Publication Date Title
MXPA04005444A (es) Ureas de 2-aminobenzotiazoles como moduladores de adenosina.
YU96502A (sh) Derivati benzotiazola
SE0104334D0 (sv) Therapeutic agents
AU9189301A (en) Use of substituted imidazo(1,2-A)pyridine-, imidazo(1,2-A)pyrimidine and imidazo(1,2-A)pyrazine-3-YL-amine derivatives for producing NOS-inhibiting medicaments
AU2002359164A8 (en) Use of oxindole derivatives in the treatment of dementia related diseases, alzheimer&#39;s disease and conditions associated with glycogen synthase kinase-3
TW200420550A (en) Thiazole compounds for the treatment of neurodegenerative disorders
CA2501799A1 (en) Pyrazole compounds for treatment of neurodegenerative disorders
DK0975595T3 (da) Kokainanaloger
MY129422A (en) Medicinal compounds
TNSN04165A1 (en) Substituted hydroxyethylamines
BR0315283A (pt) Composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, uso de um composto, e, método de tratamento de doenças neurológicas ou de doenças inflamatórias do trato respiratório superior
CA2401229A1 (en) Aryl fused azapolycyclic compounds
ATE253918T1 (de) Verwendung von hymenialdisin und dessen derivaten zur herstellung therapeutischer mittel
AU5584901A (en) Use of cyclic gmp-specific phosphodiesterase inhibitors for treatment of parkinson&#39;s disease
WO2002065979A3 (en) (diazolo-pyridinyl)-pyrimidines for use in treatment of cns disorders and diabetes
PT1696905E (pt) 2-aminotetralinas substituídas para o tratamento preventivo da doença de parkinson
WO2003027068A3 (en) Substituted amines for the treatment of neurological disorders
TW200745135A (en) Therapeutic agents
MY135218A (en) 2,6-quinolinyl and 2,6-naphthyl derivatives and their use in the treatment of vla-4 dependent diseases
TW200502221A (en) Novel lactams and uses thereof
CA2498291A1 (en) Diazabicyclic compounds useful in the treatment of cns and other disorders
AU2002359162A1 (en) Use of oxindole derivatives in the treatment of dementia related diseases, alzheimer&#39;s disease and conditions associated with glycogen synthase kinase-3
MXPA05014201A (es) Pirazolo [3,4-b] piridin-6-onas como inhibidores de la gsk-3.
MXPA05013628A (es) Pirazolo[3,4-b]piridin-6-onas como inhibidores de gsk-3.
BG104983A (en) Aryl fused azapolycyclic compounds

Legal Events

Date Code Title Description
FG Grant or registration